(FAGR) Fagron - BR
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: BR (Belgium) | Market Cap: 1.790m EUR | Total Return: 10.1% in 12m
Avg Turnover: 2.15M
Warnings
No concerns identified
Tailwinds
Confidence
Fagron NV is a Belgium-based pharmaceutical company specializing in personalized medicine through compounding services. The firm operates via three primary segments: Essentials, Brands, and Compounding Services, providing customized pharmaceutical solutions to hospitals, clinics, and pharmacies globally. Its portfolio includes specialized delivery systems such as SyrSpend SF for liquid stability and Pentravan for transdermal drug delivery.
The pharmaceutical compounding sector serves a critical niche by creating medications tailored to specific patient needs that mass-produced drugs cannot meet, such as unique dosages or the removal of allergens. Unlike traditional manufacturers, compounding businesses focus on value-added services and proprietary excipients to improve patient compliance and treatment efficacy. Investors can further explore the companys financial health and valuation metrics on ValueRay.
Founded in 1990 and formerly known as Arseus NV, the company also maintains the Fagron Academy to provide professional development for healthcare providers. This educational integration helps secure its position within the healthcare supply chain by training prescribers on the application of its proprietary dermatological and oral formulations.
- North American sterile compounding outsourcing facilities drive revenue growth and margin expansion
- Global pharmaceutical compounding demand increases amid drug shortages and personalized medicine trends
- Strategic acquisitions in fragmented markets accelerate geographic footprint and market share gains
- Regulatory compliance and quality standards evolution impact operational costs and competitive positioning
| Net Income: 91.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.76 > 1.0 |
| NWC/Revenue: 25.61% < 20% (prev 19.25%; Δ 6.36% < -1%) |
| CFO/TA 0.10 > 3% & CFO 128.3m > Net Income 91.0m |
| Net Debt (383.8m) to EBITDA (185.0m): 2.07 < 3 |
| Current Ratio: 2.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (73.2m) vs 12m ago 0.24% < -2% |
| Gross Margin: 51.47% > 18% (prev 33.67%; Δ 17.79% > 0.5%) |
| Asset Turnover: 81.85% > 50% (prev 80.47%; Δ 1.37% > 0%) |
| Interest Coverage Ratio: 5.17 > 6 (EBIT TTM 147.6m / Interest Expense TTM 28.6m) |
| A: 0.20 (Total Current Assets 462.8m - Total Current Liabilities 219.0m) / Total Assets 1.24b |
| B: -0.02 (Retained Earnings -28.1m / Total Assets 1.24b) |
| C: 0.13 (EBIT TTM 147.6m / Avg Total Assets 1.16b) |
| D: 0.80 (Book Value of Equity 551.6m / Total Liabilities 686.9m) |
| Altman-Z'' = 2.91 = A |
| DSRI: 1.06 (Receivables 95.2m/82.0m, Revenue 952.2m/872.0m) |
| GMI: 0.65 (GM 33.67% / 51.47%) |
| AQI: 0.95 (AQ_t 0.48 / AQ_t-1 0.51) |
| SGI: 1.09 (Revenue 952.2m / 872.0m) |
| TATA: -0.03 (NI 91.0m - CFO 128.3m) / TA 1.24b) |
| Beneish M = -3.25 (Cap -4..+1) = AA |
As of June 20, 2026, the stock is trading at EUR 24.20 with a total of 170,910 shares traded.
Over the past week, the price has changed by -2.22%,
over one month by -0.41%,
over three months by +11.08% and
over the past year by +10.09%.
Fagron has no consensus analysts rating.
P/E Trailing = 19.6774
P/E Forward = 16.9492
P/S = 1.8796
P/B = 3.2912
P/EG = 15.8442
Revenue TTM = 952.2m EUR
EBIT TTM = 147.6m EUR
EBITDA TTM = 185.0m EUR
Long Term Debt = 412.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 11.6m EUR (from shortTermDebt, last quarter)
Debt = 568.7m EUR (from shortLongTermDebtTotal, last quarter) + Leases 55.9m
Net Debt = 383.8m EUR (calculated: Debt 568.7m - CCE 184.9m)
Enterprise Value = 2.17b EUR (1.79b + Debt 568.7m - CCE 184.9m)
Interest Coverage Ratio = 5.17 (Ebit TTM 147.6m / Interest Expense TTM 28.6m)
EV/FCF = 16.68x (Enterprise Value 2.17b / FCF TTM 130.3m)
FCF Yield = 5.99% (FCF TTM 130.3m / Enterprise Value 2.17b)
FCF Margin = 13.68% (FCF TTM 130.3m / Revenue TTM 952.2m)
Net Margin = 9.56% (Net Income TTM 91.0m / Revenue TTM 952.2m)
Gross Margin = 51.47% ((Revenue TTM 952.2m - Cost of Revenue TTM 462.1m) / Revenue TTM)
Gross Margin QoQ = 57.26% (prev 45.67%)
Tobins Q-Ratio = 1.75 (Enterprise Value 2.17b / Total Assets 1.24b)
Interest Expense / Debt = 5.02% (Interest Expense 28.6m / Debt 568.7m)
Taxrate = 22.17% (26.1m / 117.6m)
NOPAT = 114.9m (EBIT 147.6m * (1 - 22.17%))
Current Ratio = 2.11 (Total Current Assets 462.8m / Total Current Liabilities 219.0m)
Debt / Equity = 1.03 (Debt 568.7m / totalStockholderEquity, last quarter 551.6m)
Debt / EBITDA = 2.07 (Net Debt 383.8m / EBITDA 185.0m)
Debt / FCF = 2.95 (Net Debt 383.8m / FCF TTM 130.3m)
Total Stockholder Equity = 506.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.82% (Net Income 91.0m / Total Assets 1.24b)
RoE = 17.96% (Net Income TTM 91.0m / Total Stockholder Equity 506.8m)
RoCE = 16.07% (EBIT 147.6m / Capital Employed (Equity 506.8m + L.T.Debt 412.1m))
RoIC = 11.63% (NOPAT 114.9m / Invested Capital 988.1m)
WACC = 5.83% (E(1.79b)/V(2.36b) * Re(6.44%) + D(568.7m)/V(2.36b) * Rd(5.02%) * (1-Tc(0.22)))
Discount Rate = 6.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.44 | Cagr: 0.38%
[DCF] Terminal Value 77.97% ; FCFF base≈111.6m ; Y1≈128.0m ; Y5≈188.3m
[DCF] Fair Price = 33.41 (EV 2.83b - Net Debt 383.8m = Equity 2.45b / Shares 73.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.55 | Revenue CAGR: 11.90% | SUE: 0.04 | # QB: 0
EPS current Year (2026-12-31): EPS=1.47 | Chg30d=N/A | Revisions=+11% | GrowthEPS=+18.3% | GrowthRev=+18.4%
EPS next Year (2027-12-31): EPS=1.65 | Chg30d=N/A | Revisions=+33% | GrowthEPS=+11.7% | GrowthRev=+8.5%
[Analyst] Revisions Ratio: +33%